疫苗诱导的免疫性血小板减少症和血栓形成中PF4抗体的自然史
该研究在大型患者队列中连续检测抗PF4/聚阴离子抗体、血小板和D-二聚体,并分析其与复发的关系。Stago法检测51%患者诊断后100天抗PF4/聚阴离子抗体持续阳性,而Immucor法监测94%患者持续阳性。PF4法阳性中位持续时间87天,中位随访105天后72%患者仍阳性;复发率12.6%,所有复发患者PF4抗体持续阳性且血小板下降,仅1例血栓扩展。
要点
- Stago法检测51%患者诊断后100天抗PF4/聚阴离子抗体持续阳性,Immucor法监测94%患者持续阳性。
- PF4法阳性中位持续时间87天,中位随访105天后72%患者仍阳性。
- 复发率12.6%,所有复发患者PF4抗体持续阳性且血小板下降,仅1例血栓扩展。
核心结论
- 尽管72%患者PF4抗体持续阳性,但复发率低,且似乎未导致初始就诊时所见侵袭性临床表现复发。
研究设计与样本
- 在大型患者队列中连续检测抗PF4/聚阴离子抗体、血小板和D-二聚体,并分析其与复发的关系。
主要发现
- Stago法检测51%患者诊断后100天抗PF4/聚阴离子抗体持续阳性,而Immucor法监测94%患者持续阳性。
- PF4法阳性中位持续时间87天,中位随访105天后72%患者仍阳性。
- 血浆置换在急性期似乎比其他治疗更快速降低抗PF4/聚阴离子水平并提高血小板计数。
- 复发率12.6%,所有复发患者PF4抗体持续阳性且血小板下降,仅1例血栓扩展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily adenoviral-based vaccines associated with the presence of antibodies to a PF4/polyanion neoepitope and measured by using enzyme-linked immunosorbent assays. Presented are serial anti-PF4/polyanion antibody, platelet, and D-dimer measurements in a large cohort of patients and their relation to relapse. Overall, 51% of patients using the Stago assay had persistently positive anti-PF4/polyanion levels 100 days' postdiagnosis, whereas 94% of patients monitored by using the Immucor assay remain positive. The median duration of positivity of the PF4 assay is 87 days, with 72% of patients remaining positive after a median follow-up of 105 days. The use of plasma exchange seemed to reduce anti-PF4/polyanion levels and increase platelet counts in the acute setting more rapidly than other therapies. The rate of relapse in this study was 12.6%, with all relapsed cases exhibiting persistently positive PF4 antibodies and falling platelet counts. Only one patient had extension of their thrombosis. Overall, despite the persistence of PF4 antibodies in 72% of patients, the rate of relapse was low and did not seem to result in recrudescence of the aggressive clinical picture seen at index presentation. Monitoring of these patients in the UK cohort is ongoing and will aid in definition of the natural history of this novel condition.
引用
- Craven B, Lester W, Boyce S, et al. Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood. 2022. PMID: 35263420. doi:10.1182/blood.2021014684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。